Immix Biopharma (NASDAQ:IMMX) Stock Rating Lowered by Wall Street Zen

Immix Biopharma (NASDAQ:IMMX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Mizuho started coverage on shares of Immix Biopharma in a report on Monday. They set an “outperform” rating and a $14.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immix Biopharma presently has an average rating of “Hold” and an average price target of $11.00.

Immix Biopharma Stock Performance

Immix Biopharma stock opened at $7.33 on Friday. The stock has a market cap of $388.20 million, a PE ratio of -9.52 and a beta of 0.31. The stock has a 50-day moving average of $5.74 and a two-hundred day moving average of $3.87. Immix Biopharma has a one year low of $1.34 and a one year high of $7.73.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IMMX. Allworth Financial LP purchased a new stake in Immix Biopharma in the fourth quarter valued at $30,000. Velan Capital Investment Management LP acquired a new position in Immix Biopharma in the second quarter valued at approximately $52,000. Mathes Company Inc. purchased a new stake in Immix Biopharma in the 4th quarter worth approximately $56,000. Tocqueville Asset Management L.P. grew its stake in shares of Immix Biopharma by 37.4% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after purchasing an additional 10,950 shares during the period. Finally, Imprint Wealth LLC purchased a new position in shares of Immix Biopharma during the 3rd quarter valued at approximately $141,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.